Soybean

Soybean (Glycine max): A Comprehensive Reference on Identity, Composition, Traditional Use, and Scientific Evidence

1. Identity and Botanical Classification

The soybean, soy bean, or soya bean (Glycine max) is a species of legume native to East Asia, widely grown for its edible bean. It belongs to the family Fabaceae (Leguminosae), subfamily Faboideae, and is the domesticated form of the wild species Glycine soja, which remains the closest wild relative. Soy is a staple crop, the world's most grown legume, and an important animal feed. Soy is a key source of food, useful both for its protein and oil content.

Soy was most likely domesticated 6,000–9,000 years ago in the region between the Yellow River and the Huai River in China. There is evidence for soybean domestication between 7000 and 6600 BC in China, between 5000 and 3000 BC in Japan, and 1000 BC in Korea. The earliest documented evidence for the use of Glycine of any kind comes from charred plant remains of wild soybean recovered from Jiahu in Henan province, a Neolithic site occupied between 9,000 and 7,800 years ago.

1.1 Common Names and Synonyms

• Scientific name: Glycine max (L.) Merr.
• English: Soybean, soya bean, soy
• Chinese: Dàdòu (大豆), meaning "great legume"
• Japanese: Daizu (大豆)
• Korean: Meju kong

The Chinese make liberal use of many legumes, but none of these compare in significance to the one they call the "great legume" or the "yellow legume." In fact, the soybean is so central to the Chinese food system that it is often simply referred to as "the legume," its full name only deemed necessary when distinguishing it from other types.

1.2 Common Forms and Preparations

Traditional unfermented food uses of soybeans include edamame, as well as soy milk, from which tofu and tofu skin are made. Fermented soy foods include soy sauce, fermented bean paste, nattō, and tempeh. In supplement contexts, soybean is available in several distinct forms:

• Whole soybean (mature and green/edamame): Consumed directly as a whole food.
• Soy milk: Made by soaking and grinding whole soybeans and stirring, or hydrating whole, full-fat soy flour to form a rich, creamy liquid.
• Tofu (bean curd): Produced from soybeans by soaking, grinding, boiling, and adding different coagulating agents.
• Miso: A fermented soybean paste, often made by a double fermentation process from a combination of soybeans and a cultured grain, such as rice or barley.
• Soy sauce: Perhaps the most famous use of the soybean, brewed (like beer) from fermented soybeans mixed with water, wheat, and salt.
• Soy protein isolate (SPI): A highly processed powder in which protein constitutes at least 90% of content by weight, used widely in clinical research and supplementation.
• Soy protein concentrate: A less refined form retaining more fiber and carbohydrate than SPI.
• Soy isoflavone extracts: Soy supplements may contain soy protein, isoflavones (compounds similar in structure to the hormone estrogen), or other components.
• Soybean oil: Widely used in cooking, as well as in industry.
• Nattō: A fermented whole-bean product traditional to Japan, produced using Bacillus subtilis fermentation.
• Tempeh: An Indonesian fermented whole-bean cake produced using Rhizopus mold.

2. History and Traditional Use

2.1 Ancient China

In 2838 B.C., Chinese Emperor Sheng-Nung wrote the Materia Medica — the first written record of soybean cultivation. In that record, soybeans were noted as being valued for their medicinal purposes. Soybeans were first cultivated in northern China. From there, their use spread into Japan, Korea, and the rest of Southeast Asia. The soybean is mentioned in medical records from China, Egypt, and Mesopotamia that date from 1500 B.C. or earlier.

An important food in the Asian diet for centuries, green soybean is one of the most protein-rich vegetable cultures, used in China as food and medicine for around 4,000 to 5,000 years. In ancient times, moldy and fermented substances from soybeans were commonly used as primitive antibiotics to treat wounds and reduce swelling.

2.2 Japan and Korea

Soy foods have a long history of use in North East Asia in particular, and each country has developed its own soy-based cuisine that appeals to local preferences. There is a wide variety of soy foods, and they are an intrinsic part of shojin ryori, vegan food eaten by Buddhist monks in Japan and other Asian countries. Tofu traveled throughout East and Southeast Asia with Chinese migrants and Buddhist monks, for whom it was a valuable source of vegetarian protein, but the predominant modes of processing varied from region to region. Soybean sprout soup is common in Korea, while soybean sauce soup is often eaten in Japan.

2.3 Traditional Fermented Products

Even in its early history, the soybean was highly regarded and the source of a wide variety of foods. The three most important soy foods in traditional Asian cuisine were miso, tempeh, and tofu. Traditional processing included extensive use of fermentation, which often results in products with strong flavors. Soy sauce is just one example, and became the most widely available fermented legume product in the world.

2.4 Spread to Europe, South Asia, and the Americas

By the 17th century, through their trade with the Far East, soybeans and their products were traded by European traders (Portuguese, Spanish, and Dutch) in Asia. By the 18th century, soybeans were introduced to the Americas and Europe from China. Soy first reached Western shores as imported soy sauce, and soybeans were being grown in Europe by the 18th century. In 1765, the first soybean plant reached North American soil. Soy was introduced to Africa from China in the late 19th century, and is now widespread across the continent.

3. Chemical Composition and Key Constituents

3.1 Macronutrient Profile

The macronutrient composition of the soybean differs markedly from other legumes as it is much higher in fat, moderately higher in protein, and much lower in carbohydrate. The soybean is notable not only for its total protein content but the quality of soy protein, which is higher than that of other plant proteins and similar to animal protein. The protein digestibility corrected amino acid scores (PDCAAS) for soy protein range from 0.9 to 1.0 depending upon the specific soy food in question.

3.2 Proteins

The primary storage proteins in soybeans are glycinin (11S) and β-conglycinin (7S), which together account for roughly 80% of total soybean protein. Soy protein is considered a complete protein, containing all essential amino acids. Evidence indicates that the digestibility of protein from traditional Asian soy foods is quite good. Isolated soy protein (ISP) is by definition at least 90% protein by weight.

3.3 Isoflavones (Phytoestrogens)

Isoflavones are the most extensively studied bioactive constituents of soybean. The various isoflavones present in soybean hypocotyls are classified into four classes according to their chemical structures: (i) aglycones (daidzein, genistein, and glycitein); (ii) glycosides (daidzin, genistin, and glycitin); (iii) acetyl glycosides; and (iv) malonyl glycosides.

After ingestion, β-glucosidases in the intestinal wall hydrolyze the glycosides, resulting in conversion to their corresponding bioactive aglycones, genistein and daidzein. Only these aglycone forms are absorbed and are therefore biologically active.

Soy phytoestrogens, such as genistein, daidzein, and glycitein, are isoflavonoids closely related to human 17β-estradiol, but with lower estrogenic activity. Of the soy isoflavones, genistein and daidzein, in particular, have been studied, but recently, equol as a derivative has gained interest because it is more biologically potent. Equol is a metabolite of daidzein produced by intestinal bacteria; not all individuals produce equol, and this variability is considered to explain much of the inter-individual differences in response to soy isoflavone interventions.

3.4 Lipids and Fatty Acids

Oleic acid is one of the five most abundant fatty acids in soybean seeds. The lipid fraction also contains significant amounts of linoleic acid (omega-6) and alpha-linolenic acid (omega-3). The soybean is low in saturated fat and a source of both essential fatty acids, the omega-6 fatty acid linoleic acid and the omega-3 fatty acid alpha-linolenic acid.

3.5 Minerals and Vitamins

Key minerals concentrated in soybeans include potassium, phosphorus, magnesium, calcium, and iron, along with trace elements such as molybdenum, copper, and manganese. The dietary fiber content spans both soluble and insoluble fractions and supports digestive health, assists blood sugar regulation, and contributes to cholesterol management.

3.6 Other Bioactive Non-Isoflavone Phytochemicals

Other phytochemicals, either alone or in combination with isoflavones or soy protein, may be involved in the health effects of soy. These include saponins, phytic acid, protease inhibitors, lignans, and phytosterols.

Saponins in soybeans have been linked to cholesterol reduction in animal studies and are recognized as contributors to the broader anti-cancer and cardioprotective effects of soy consumption. Phytic acid, while often labeled an antinutrient because it binds to minerals like iron and zinc and reduces their bioavailability, has been re-evaluated; compounds previously classified as antinutritional factors, including phytic acid and protease inhibitors, are now understood to exert anticarcinogenic and antimutagenic effects under certain conditions. Standard food processing methods such as boiling, fermentation, and soaking substantially reduce the activity of these compounds, improving overall digestibility and mineral absorption.

4. Mechanisms of Action

4.1 Estrogenic and Anti-Estrogenic Activity

Genistein, one of the predominant soy isoflavones, has been shown to compete with 17β-estradiol for estrogen receptor binding because of its structural similarity, resulting in agonistic or antagonistic activity. Isoflavones have been shown in numerous studies to activate estrogen receptors in the vagina, oocytes, and mammary glands; in addition, depending on their physiological environment or chemical makeup, they may have estrogenic or antiestrogenic actions.

In vitro studies have shown that both genistein and daidzein stimulate the proliferation of MCF-7 human estrogen-receptor alpha positive (ERα+) breast cancer cells at low concentrations, but inhibit tumor growth at higher doses. In ER-alpha negative (ERα−) cells, this biphasic effect is not observed; both phytoestrogens exhibit an anti-proliferative effect only. This indicates that the proliferative effect of genistein and daidzein, as observed at low doses, is ERα-mediated, while ERβ seems to oppose ERα actions and exhibits anti-migratory and anti-invasive properties.

4.2 Tyrosine Kinase and Cell Signaling Inhibition

In membrane preparations from mammalian cells, genistein is a potent and specific inhibitor of tyrosine autophosphorylation of the epidermal growth factor (EGF) receptor. However, in several cell systems in which it inhibits growth, genistein does not alter tyrosine phosphorylation of the EGF receptor or other tyrosine kinase substrates thought to be involved in signal transduction pathways, suggesting that other mechanisms may be responsible for its action. Alternatives include inhibition of DNA topoisomerase II activity, regulation of cell cycle checkpoints, and antiangiogenic and antioxidant activity.

It is suggested that genistein possesses pleiotropic molecular mechanisms of action including inhibition of tyrosine kinases, DNA topoisomerase II, 5α-reductase, protein histidine kinase, and cyclin-dependent kinases, modulation of different signaling pathways associated with the growth of cancer cells (e.g., NF-κB, Akt, MAPK). Moreover, genistein is also a potent inhibitor of angiogenesis.

4.3 Anti-Inflammatory Mechanisms

Soy isoflavones are able to inhibit nitric oxide (NO) production. It has been reported that genistein can down-regulate NO synthase in chondrocytes by inhibiting tyrosine kinase. Isoflavones could decrease the expression of inducible nitric oxide synthase (iNOS), NF-κB, and STAT1. Cyclooxygenase-2 inhibition is another mechanism of action of isoflavones, which is regulated by the nuclear factor NF-κB.

4.4 Lipid-Lowering Mechanisms

Soy protein may exert its lipid-lowering effect through reducing the activity of lipoprotein lipase. Soybeans contain additional components, such as isoflavones, lecithins, saponins, and fiber, that may improve cardiovascular health through independent mechanisms.

4.5 Bone Metabolism

Evidence from epidemiologic studies supports that dietary soy isoflavones attenuate menopause-induced osteoporotic bone loss by decreasing bone resorption and stimulating bone formation. Soy isoflavones, acting as selective estrogen receptor modulators (SERMs), may bind to estrogen receptors in bone tissue and mimic estrogen's inhibitory effects on osteoclast-mediated resorption.

4.6 TGF-β Signaling

Experiments suggest a concept that genistein may inhibit cell growth by modulating transforming growth factor (TGF) β1 signaling pathways.

5. Scientific Evidence by Health Area

5.1 Cardiovascular Health and Lipid Profile

Overview: This is one of the most thoroughly studied areas for soy. Consuming soy protein in place of other proteins may lower cholesterol levels to a small extent. Soy isoflavones may not have the same effect.

LDL and Total Cholesterol: Inspection of the individual trial estimates indicated most trials (~75%) showed a reduction in LDL cholesterol (range: −0.77 to −58.60 mg/dL), although only a minority of these were individually statistically significant. Soy protein significantly reduced LDL cholesterol by approximately 3–4% in adults.

A systematic review and meta-analysis focused on postmenopausal women (2,305 participants across included studies) found that changes in lipid profile showed statistically significant decreases of total cholesterol by −4.64 mg/dL (95% CI: −8.12, −1.16) and increased HDL-cholesterol by 1.15 mg/dL (95% CI: 0.00, 1.93), while LDL cholesterol and triacylglycerol changes did not reach statistical significance. The results suggest that soy and its isoflavones can be effective in correcting changes in lipid metabolism in postmenopausal women and may favorably influence the prevention of cardiovascular events.

A meta-analysis of randomized controlled trials in type 2 diabetes patients found that soy product consumption led to a significant reduction in serum concentrations of triglycerides (WMD: −24.73 mg/dL), total cholesterol (WMD: −9.84 mg/dL), LDL cholesterol (WMD: −6.94 mg/dL), and C-reactive protein (WMD: −1.27 mg/L). In contrast, soy products had no effect on HDL cholesterol, fasting blood sugar, fasting insulin, glycated hemoglobin, HOMA-IR, systolic blood pressure, diastolic blood pressure, or BMI.

Isoflavone-Specific Evidence: An American Heart Association Science Advisory noted that among 19 studies of soy isoflavones, the average effect on LDL cholesterol and other lipid risk factors was nil. The advisory concluded that earlier research indicating that soy protein has clinically important favorable effects as compared with other proteins has not been confirmed. In contrast, many soy products should be beneficial to cardiovascular and overall health because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low content of saturated fat.

Endothelial Function: Isoflavones improve endothelial function and possibly slow the progression of subclinical atherosclerosis.

Evidence Strength: Moderate. The cholesterol-lowering effect of soy protein (as opposed to isolated isoflavones) is supported by multiple RCTs and meta-analyses. The effect size is modest (~3–4% LDL reduction). The effects of isolated isoflavone supplements on lipids are inconsistent and not well established. The available meta-analyses indicate an inverse association between soy consumption and CVD. Additionally, there is a probable beneficial effect of isoflavones, but the beneficial effect of protein on endpoints of CVD cannot be fully confirmed yet. Recent evidence suggests an inverse association between soy and endpoints of CVD.

5.2 Menopausal Symptoms (Vasomotor Symptoms / Hot Flashes)

Soy isoflavone supplements or soy protein may help to reduce the frequency and severity of menopausal hot flashes, but the effect may be small, and research results have been mixed. Isoflavone supplements consistently alleviate menopausal hot flashes provided they contain sufficient amounts of the predominant soybean isoflavone genistein.

Meta-analytic evidence in postmenopausal women indicates that soy isoflavones are effective in improving bone mineral density and reducing the symptoms of menopause, predominantly hot flashes; they also improve oxidative stress, glycemia, and lipid abnormalities. In terms of safety, no long-term human studies are available and short-term evidence indicates they have an acceptable safety profile comparable to that of a placebo. Though some evidence indicates soy isoflavones are as effective as hormone replacement therapy, they may not be considered an alternative.

Evidence Strength: Moderate. Meta-analyses support a modest reduction in hot flash frequency and severity, particularly with genistein-enriched supplements. However, variability in isoflavone content of products, differences in equol-producer status, and trial heterogeneity limit definitive conclusions.

5.3 Bone Mineral Density and Osteoporosis

A systematic review and meta-analysis of 18 RCTs (published 1995–2019) found that daily intake of 106 mg (range, 40–300 mg) of isoflavones for 6–24 months moderately but statistically significantly positively affects bone mineral density (BMD), compared with controls: lumbar spine WMD = 1.63%, femoral neck WMD = 1.87%, and total hip WMD = 0.39%. Subgroup analyses indicated that the varying effects of isoflavones on BMD across the trials might be associated with intervention duration, racial diversity (Caucasian, Asian), time after menopause, form of supplements (especially genistein), and dose of isoflavones. This review and meta-analysis suggests that soy isoflavones are effective in slowing down bone loss after menopause.

The OPUS Study — a two-year randomized, placebo-controlled trial in healthy menopausal women — compared placebo with daily supplementation of soy hypocotyl isoflavones. The primary outcome measure revealed that 120 mg soy isoflavones reduce whole body bone loss but do not slow bone loss at common fracture sites. An investigation of mammographic density, a marker of breast cancer risk, found that two years of supplementation did not adversely modify breast density in this population of postmenopausal women.

An older review noted that the evidence that isoflavones reduce bone loss in postmenopausal women is unimpressive, reflecting the mixed results that characterized earlier literature.

NCCIH states that soy isoflavones probably have a beneficial effect on bone density in postmenopausal women.

A prospective cohort study in China also found that soy food consumption was associated with a significantly lower risk of fracture, particularly among women in the early years after menopause.

Evidence Strength: Moderate, with meta-analytic support from RCTs. Effect sizes are small to moderate. Benefits appear most pronounced in early postmenopause and may be greatest in individuals who produce equol from daidzein. Fracture risk reduction data come primarily from observational studies.

5.4 Cancer — Breast Cancer

Epidemiological studies have revealed that high consumption of soy products is associated with low incidences of hormone-dependent cancers, including breast and prostate cancer.

A 2022 meta-analysis cited in the literature found that soy consumption may reduce the risk of breast cancer both in pre- and postmenopausal women and also improve the prognosis of patients with a breast cancer diagnosis. A prospective study of 300,000 Chinese women found that each 10 mg/day increment in soy isoflavone intake was associated with a 3% reduced risk of breast cancer, but low and moderate soy intake had no influence on breast cancer risk in the Chinese women population.

However, in vitro and supplementation data must be interpreted with caution. The beneficial effect of dietary soy food intake, especially for women diagnosed with breast cancer, is controversial, as in vitro data has shown that the soy isoflavones genistein and daidzein may even stimulate the proliferation of estrogen-receptor alpha positive (ERα+) breast cancer cells at low concentrations.

An American Heart Association advisory found that the efficacy and safety of soy isoflavones for preventing or treating cancer of the breast, endometrium, and prostate are not established; evidence from clinical trials is meager and cautionary with regard to a possible adverse effect. For this reason, use of isoflavone supplements in food or pills is not recommended.

The OPUS Study safety data were reassuring: soy hypocotyl isoflavone supplementation data do not indicate that soy or soy isoflavone exposure increases breast cancer risk, and accumulating data in the literature support this.

Soy products in supplement form have not been shown to reduce breast cancer risk, per the NCCIH.

Evidence Strength: Mixed. Epidemiological data from Asian populations suggest a protective association, but evidence is predominantly observational. Clinical trials are limited. The in vitro biphasic dose-response (stimulatory at low concentrations, inhibitory at higher concentrations) in ER+ cell lines adds complexity. The use of concentrated isoflavone supplements by women with existing hormone-receptor-positive breast cancer or those on anti-estrogen therapy (e.g., tamoxifen) requires caution.

5.5 Cancer — Prostate Cancer

Meta-analyses have shown that consumption of soy and/or phytoestrogens, including soy isoflavones, reduced the risk of developing certain cancers, including prostate, breast, endometrial, and gastric cancer, as well as colon and colorectal cancer, although the evidence for the latter malignancy is inconsistent.

A meta-analysis of 22 observational studies comprising 1,409,213 participants found that soy products reduce the risk of prostate cancer (OR=0.94, 95% CI=0.91–0.97, p<0.001), especially in cases of localized or low-grade prostate cancer, but exhibit no effect on non-localized or high-grade prostate cancer.

A randomized, placebo-controlled six-month pilot trial examined the effect of 6–8 month soy protein supplementation on PSA serum levels in men who recurred within three years of prostatectomy. Sixteen men were randomized to 20 g soy protein (~24–26 mg/day genistein; ~40–43 mg/day total isoflavones) or casein placebo. PSA was measured at baseline and at 1, 2, 4, and 6–8 months. Serum genistein levels greatly increased from baseline and cholesterol decreased in the soy group.

An 18-month randomized, placebo-controlled trial using 19.2 g/day of whole soy protein isolate containing 24 mg genistein found that 18 months of consumption reduced circulating testosterone and SHBG, but not free testosterone, and did not affect serum concentrations of estradiol, VEGF, IGF-1, IGFBP-3, IGF-1/IGFBP-3 ratio, soluble Fas, Fas-ligand, and sFas/Fas-ligand ratio.

Different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers. Many of these mechanisms could also be demonstrated in the prostate, both in vitro and in vivo. It is important to stress that most of the results in this area were obtained with in vitro studies, where it is generally believed that plant molecules such as isoflavones may have a more pronounced effect when applied directly to cell culture versus in vivo.

Randomized clinical trials of the effect of soy consumption on cancer risk and mortality are needed, but only a few have been reported.

Evidence Strength: Preliminary to moderate. Observational meta-analyses suggest a modest inverse association with localized prostate cancer risk. Clinical trial evidence is limited by small sample sizes and short durations.

5.6 Type 2 Diabetes and Glycemic Control

People who consume diets high in soy may have a lower risk of type 2 diabetes. It is uncertain whether soy products improve control of blood sugar in people who already have type 2 diabetes.

A systematic review and meta-analysis of RCTs in type 2 diabetes patients found that there was a significant reduction in fasting blood sugar after soy consumption in patients with elevated baseline fasting blood sugar (>126 mg/dL) and in those who received higher doses of soy intake (>30 g/day). Moreover, soy products decreased systolic blood pressure in patients with baseline hypertension (>135 mm Hg).

In a systematic review and meta-analysis of 8 trials, it was concluded that soy products have beneficial effects in type 2 diabetes patients in relation to serum lipids without a significant effect on fasting glucose, insulin, and glycated hemoglobin (HbA1c). It seems that soy isoflavones can increase serum insulin by enhancing insulin signaling, and eventually improve glucose uptake.

Evidence Strength: Mixed. Evidence suggests modest benefit on lipids in T2D patients and potential glucose-lowering effects at higher doses or in individuals with elevated baseline glucose, but effects on HbA1c and insulin are not consistently demonstrated. Further large, well-controlled RCTs are needed.

5.7 Blood Pressure

Consumption of soy isoflavones may lead to a modest decrease in blood pressure. This effect was detected primarily in observational and intervention studies in hypertensive subgroups. The current evidence does not support hypotensive effects of soy components such as protein, fiber, lecithins, and saponins as robustly as for isoflavones.

Evidence Strength: Preliminary. Effect sizes are small and evidence is not entirely consistent. Subgroup analyses suggest benefit may be confined to those with elevated baseline blood pressure.

5.8 Cognitive Function

It is uncertain whether soy has beneficial effects on cognitive function; studies have had conflicting results. Several clinical trials have investigated soy isoflavone supplementation on memory, attention, and cognitive performance, particularly in older adults and postmenopausal women, but results have been inconsistent across study designs and populations.

Evidence Strength: Insufficient. The evidence base is limited, heterogeneous, and currently does not permit definitive conclusions.

6. Body Systems and Health Areas

• Cardiovascular system: Effects on LDL cholesterol, total cholesterol, triglycerides, blood pressure, endothelial function, and atherosclerosis markers.
• Endocrine system / Menopausal health: Phytoestrogenic activity influencing vasomotor symptoms (hot flashes), hormonal milieu in postmenopausal women.
• Skeletal system: Influence on bone mineral density and potential reduction of osteoporotic bone loss.
• Oncology: Epidemiological associations with reduced risk of hormone-dependent cancers (breast, prostate, endometrial); in vitro and in vivo mechanistic data on cell proliferation, apoptosis, angiogenesis.
• Metabolic / glycemic: Effects on blood glucose, insulin sensitivity, and lipid metabolism; potential role in T2D risk modification.
• Digestive / prebiotic: The dietary fiber content spans both soluble and insoluble fractions and supports digestive health, assists blood sugar regulation, and contributes to cholesterol management.
• Immune and inflammatory: Inhibition of NF-κB, iNOS, and COX-2 pathways by isoflavones.

7. Dosage Forms and Doses Reported in Clinical Studies

In research studies, soy protein supplements have been safely used for up to 16 weeks in many short-term trials, with longer studies extending to 18–24 months also reported in the literature.

• Soy protein isolate (lipid studies): Typical doses in clinical trials providing lipid-lowering effects range from approximately 20–40 g/day of soy protein. One pilot trial used 20 g soy protein per day (~24–26 mg/day genistein; ~40–43 mg/day total isoflavones).
• Soy isoflavones (bone mineral density studies): Daily intake of 106 mg (range, 40–300 mg) of isoflavones for 6–24 months was used in meta-analyzed RCTs.
• Soy isoflavones (menopausal hot flashes / OPUS Study): The OPUS Study compared placebo with daily supplementation of soy hypocotyl isoflavones (the equivalent of 80 or 120 mg aglycones), administered primarily as their β-glucoside conjugates in healthy menopausal women over a 2-year interval.
• Prostate cancer trial (18-month RCT): 19.2 g/day of whole soy protein isolate containing 24 mg genistein was used over 18 months.
• Type 2 diabetes benefit threshold: A significant reduction in fasting blood sugar was observed in patients who received higher doses of soy intake (>30 g/day).
• In vitro concentrations (isoflavones): In vitro studies commonly use concentrations ranging from low (0.1–5 µM) to medium (10–50 µM) and higher (200 µM). These doses are not directly translatable to clinical supplementation doses.

8. Safety Considerations and Interactions

8.1 General Safety

Soy isoflavones have been a component of the diet of certain populations for centuries. The consumption of soy generally has been considered beneficial, with a potentially protective effect against a number of chronic diseases; because of their estrogenic activity, however, negative effects of isoflavones have been postulated. When viewed in its entirety, the current literature supports the safety of isoflavones as typically consumed in diets based on soy or containing soy products.

8.2 Soy Allergy

Soy is one of the eight major food allergens (FDA, 2018). Some people are allergic to soy. Allergic reactions can range from mild (urticaria, gastrointestinal symptoms) to, rarely, anaphylaxis. Individuals with known soy allergy should avoid all soy-containing products.

8.3 Thyroid Function

Soy foods have had an important dietary role in Asian countries for centuries, and in recent years they have become increasingly popular in Western countries. Nevertheless, there are some concerns that soy can have a negative effect on thyroid function and can alter the levels of thyroid hormones. A systematic review found that the European Food Safety Authority (EFSA) concluded soy isoflavones were without effect on thyroid function. Furthermore, a review of studies found that there is no evidence suggesting that isoflavone exposure increases blood estrogen levels in men. Neither soy foods nor isoflavone supplements altered levels of reproductive hormones, such as testosterone, in men. Also, no effects were found on thyroid hormones.

However, soybean flour and soy-containing foods may impair the absorption of the thyroid medication levothyroxine. T4 oral absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium-fortified juices. This is a pharmacokinetic interaction affecting drug absorption, not a direct effect on thyroid gland physiology in healthy individuals.

8.4 Interaction with Warfarin

Soy milk may interact with certain medications, such as warfarin, resulting in decreased efficacy. Additionally, foods rich in vitamin K include soybeans, among other vegetables; since vitamin K antagonizes warfarin's anticoagulant effect, sudden large changes in soy food consumption may influence INR stability in patients on warfarin therapy.

8.5 Interactions with Tamoxifen and Hormone-Sensitive Conditions

Soy may interact with medications like tamoxifen that treat hormone-sensitive conditions such as breast cancer. Due to the phytoestrogenic activity of isoflavones and the demonstrated in vitro ability to influence estrogen metabolism, this interaction is of clinical interest, particularly for patients receiving hormonal therapies for breast cancer. This remains an area of active investigation; patients on such therapies should discuss soy supplement use with their oncologist.

8.6 Breast Cancer in Women with Existing Diagnoses

Based on the weak estrogen-like effects of the isoflavones genistein and daidzein, some researchers and clinicians are concerned that a high soy intake may increase the cancer risk. However, the evidence from population-level studies is generally reassuring regarding whole soy food consumption. Data from the OPUS Study do not indicate that soy or soy isoflavone exposure increases breast cancer risk, and accumulating data in the literature support this. The concern is greatest for high-dose isoflavone supplements rather than dietary soy foods.

8.7 Reproductive Hormones in Men

A review of studies found that there is no evidence suggesting that isoflavone exposure increases blood estrogen levels in men. Neither soy foods nor isoflavone supplements altered levels of reproductive hormones, such as testosterone, in men.

8.8 Antinutritional Factors and Digestive Effects

Phytic acid, while often labeled an antinutrient because it binds to minerals like iron and zinc and reduces their bioavailability, has been re-evaluated. Standard food processing methods such as boiling, fermentation, and soaking substantially reduce the activity of these compounds, improving overall digestibility and mineral absorption. Raw or inadequately processed soybeans contain trypsin inhibitors that can interfere with protein digestion, though these are inactivated by standard cooking.

References

• Wikipedia — Soybean
• National Center for Complementary and Integrative Health (NCCIH) — Soy: Usefulness and Safety
• Jenkins et al. — A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. Journal of Nutrition, 2019. PMC6543199
• Asbaghi et al. — The Effects of Soy Products on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. Advances in Nutrition, 2022. PMC8970819
• Moosavian et al. — The Effects of Soy Products on Cardiovascular Risk Factors in Patients with Type 2 Diabetes. Advances in Nutrition, 2021. PubMed 34591084
• Tokede et al. — The Effects of Soy and its Components on Risk Factors and End Points of Cardiovascular Diseases. PMC6893684
• Barańska et al. — Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women. Nutrients, 2021. PMC8398438
• Sacks et al. — Soy protein, isoflavones, and cardiovascular health: An American Heart Association Science Advisory. Circulation, 2006. PubMed 16418439
• Ramdath et al. — Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease. Nutrients, 2017. PMC5409663
• Barańska et al. — The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of RCTs. Nutrients, 2022. PMC9409780
• Liu et al. — Soy Isoflavones and Osteoporotic Bone Loss. PMC4717511
• Alekel et al. — Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women (OPUS Study). PMC3021428
• Messina M — Soy foods, isoflavones, and the health of postmenopausal women. American Journal of Clinical Nutrition, 2014. PubMed 24898224
• Andrade et al. — Soy and Breast Cancer: Focus on Angiogenesis. PMC4463727
• Zhao et al. — Intake of Soy, Soy Isoflavones and Soy Protein and Risk of Cancer Incidence and Mortality. Frontiers in Nutrition, 2022. PMC8931954
• De Groote et al. — The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects. Nutrients, 2023. PMC10708402
• Bosland et al. — Randomized, Placebo-Controlled Six-Month Intervention Study of Soy Protein Isolate in Men with Biochemical Recurrence after Radical Prostatectomy. PMC8756455
• Bosland et al. — Impact of 18-Month Soy Protein Supplementation on Steroid Hormones and Serum Biomarkers in Males Following Prostatectomy. PMC8996680
• Bhaumik et al. — Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via TGF-beta signaling pathways. PubMed 9848510
• Wu et al. — Antioxidant action of soy isoflavones on oxidative stress and antioxidant enzyme activities in exercised rats. PMC4252520
• Arjmandi et al. — Comparison of the Effects of Genistein and Daidzein with Dexamethasone and Soy Protein on Rheumatoid Arthritis in Rats. PMC3648967
• Balk et al. — Soy isoflavones: a safety review. Nutrition Reviews, 2003. PubMed 12638461
• Otun et al. — Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function. PMC6408586
• Messina M — Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature. Nutrients, 2016. PMC5188409
• Agriculture Institute — Chemical Composition and Nutritional Value of Soybeans
• Frontiers in Pharmacology — Enhancing health and therapeutic potential: innovations in the medicinal and pharmaceutical properties of soy bioactive compounds, 2024
• Illinois Corn and Soy — History of the Soybean: The Migration from Asia to America
• University of Florida IFAS Extension — Plant-Based Milks: Soy (FS422)
• Birt et al. — Non-isoflavone Phytochemicals in Soy and Their Health Effects. Journal of Agricultural and Food Chemistry, 2010